Cormorant Asset Management

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by existing therapies. The company develops epigenetic therapies, including selective histone deacetylase inhibitors, and advances candidates such as OKI-179 and OKI-422 in preclinical and clinical development. Its approach aims to directly target malignant cells, combine with other targeted therapies, and prime the tumor microenvironment to enhance immunotherapies, with a pipeline of tumor-agnostic candidates designed for optimal efficacy and tolerability.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

GondolaBio is a biopharmaceutical company dedicated to researching, developing, and manufacturing pharmaceutical products. Its primary focus is on creating therapeutics for patients with genetic diseases, addressing high unmet medical needs across various therapeutic areas and stages of development. The company leverages biological research to drive its mission, aiming to enable the healthcare industry to effectively treat and manage rare genetic conditions.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

AltruBio is a biopharmaceutical company dedicated to the development of targeted antibody therapeutics aimed at treating cancer and immune-related inflammatory diseases. With its research and development foundation established in Taipei, Taiwan, since 2000, the company focuses on addressing unmet medical needs through innovative therapeutic solutions. AltruBio has developed an efficient discovery platform that identifies and validates novel antibody therapeutics. The company is actively advancing several potential therapeutic antibodies that target various conditions, including autoimmune diseases and multiple forms of cancer, such as pancreatic, stomach, colorectal, ovarian, and lung cancers. By leveraging its expertise in antibody-drug conjugate therapy and developing specialized linker payloads, AltruBio strives to improve patient outcomes and enhance recovery from immune-mediated diseases.

Synnovation Therapeutics is a precision oncology company that specializes in the development of small molecule therapies aimed at addressing key driver mechanisms in cancer. The company is committed to discovering and advancing therapeutics that enhance the quality of life for cancer patients. By leveraging its expertise in medicinal chemistry, cancer biology, and patient-focused precision medicine, Synnovation Therapeutics cultivates a diverse pipeline of innovative targeted therapies. Its objective is to efficiently progress these agents into clinical trials, ultimately transforming the standard of care in cancer treatment and improving patient outcomes.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Nexo Therapeutics is a small molecule oncology company focused on discovering and developing innovative drugs for cancer patients who have limited therapeutic options. The company utilizes a unique platform that integrates covalent ligand discovery and chemical biology, allowing it to advance small-molecule therapies aimed at challenging and previously intractable cancer targets. By unlocking a pipeline of novel oncology treatments, Nexo Therapeutics seeks to provide medical professionals with new and effective options to improve patient outcomes in the fight against cancer.

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by existing therapies. The company develops epigenetic therapies, including selective histone deacetylase inhibitors, and advances candidates such as OKI-179 and OKI-422 in preclinical and clinical development. Its approach aims to directly target malignant cells, combine with other targeted therapies, and prime the tumor microenvironment to enhance immunotherapies, with a pipeline of tumor-agnostic candidates designed for optimal efficacy and tolerability.

Orionis Biosciences is a biotechnology company focused on early-stage drug discovery and development. It specializes in innovative medicines for diseases with high unmet medical needs, initially concentrating on oncology and immunotherapies. The company operates research facilities in Waltham, MA, USA, and Ghent, Belgium, led by an experienced team of entrepreneurs and scientists.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the precise insertion of therapeutic messages into the human genome. This innovative approach aims to address diseases at their source by enabling both small and large genetic alterations. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics seeks to overcome existing limitations in these fields, enhancing their efficacy and reach. Founded by Flagship Pioneering, the company aspires to establish a new category in genetic medicine that can significantly improve patient outcomes and transform healthcare.

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing novel therapies for inflammatory skin and joint diseases. Its flagship product, SLK, is an investigational Nanobody targeting IL-17A and IL-17F, showing potential for disease modification in dermatology and rheumatology patients.

Star Therapeutics aims to develop therapies for numerous rare diseases by identifying those with shared biological pathways. This approach enables the creation of single treatments capable of addressing multiple conditions, thereby expanding pharmaceutical pipelines.

Electra Therapeutics is a clinical stage biotechnology company focused on developing therapies aimed at treating immunological diseases and cancer. The company specializes in targeting signal regulatory proteins (SIRP) to deplete pathological immune cells. Its lead product candidate, ELA026, is a monoclonal antibody currently in clinical development for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition with no existing approved treatments. In addition to ELA026, Electra has two preclinical programs under development, highlighting its commitment to addressing unmet medical needs in the field of immunology and oncology.

Arkuda Therapeutics, Inc. is a biotechnology company founded in 2018 and based in Cambridge, Massachusetts, focused on developing innovative treatments for patients with neurological diseases. The company utilizes new insights into progranulin and lysosomal biology to create therapies that aim to correct progranulin deficiency and address lysosomal dysfunction, particularly in genetically-defined frontotemporal dementia associated with mutations in the GRN gene. By targeting these underlying biological mechanisms, Arkuda's lead compounds are designed to improve cellular health in the brain, potentially delaying the progression of neurodegenerative diseases and the onset of their symptoms.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Founded in 2019, Enliven Therapeutics is a precision oncology company based in Boulder, Colorado. It focuses on developing small molecule therapies to extend and improve patient lives by targeting clinically validated biological targets with industry-leading chemistry.

Founded in 2015, ONK Therapeutics is an Irish biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for both hematological malignancies and solid tumors. The company's proprietary platform combines chimeric antigen receptors (CARs) with tumor necrosis factor-related apoptosis-inducing ligand variants (TRAILv), enhancing NK cell efficacy against cancer cells.

Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Shoreline Biosciences, Inc. is a biotechnology company based in La Jolla, California, founded in 2020. The company specializes in developing cell-based immunotherapies aimed at treating seriously ill patients. Shoreline's proprietary technology platform leverages advanced methods in induced pluripotent stem cell (iPSC) differentiation and genetic programming, specifically targeting the IL-15/CISH pathway. This approach enhances the metabolic fitness and persistence of engineered natural killer (NK) cells, improving their anti-cancer activity. Shoreline's focus includes creating clinically effective immunotherapies using iPSC-derived NK cells and macrophages, providing innovative and cost-effective treatment options for oncology and other serious health conditions.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Umoja Biopharma is a biotechnology company specializing in innovative immunotherapy aimed at transforming cancer treatment. The company focuses on reprogramming T cells to effectively target cancer within patients' bodies, enhancing the immune response to combat both solid tumors and hematological cancers, which often show poor responses to conventional therapies. Umoja Biopharma's proprietary CAR T-cell gene therapy platform is designed to deliver scalable therapeutic regimens, allowing for tailored treatment options that can be administered to any patient, regardless of tumor type or stage. This approach aims to improve patient outcomes and quality of life by providing a safe and controllable method to attack cancer directly.

Elpiscience Biopharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company based in Pudong, China, with an additional office in Suzhou. It specializes in developing next-generation immunotherapies aimed at treating cancer. The company boasts a robust pipeline of innovative molecules that target a wide array of challenges in immuno-oncology. Founded by experienced leaders and scientists in the biopharmaceutical field, Elpiscience is committed to advancing at least one innovative molecule into clinical trials each year, with the goal of improving treatment options for cancer patients globally.

BlissBio is a biopharmaceutical company dedicated to the development of innovative drugs for tumor targeting and immunotherapy. The company specializes in creating pharmaceuticals that utilize antibody-drug conjugate (ADC) and site-specific conjugate technology platforms, which are supported by independent intellectual property rights. These platforms enable BlissBio to develop and industrialize advanced anti-tumor therapies aimed at improving treatment outcomes for cancer patients. Through its focus on targeted therapies, BlissBio aims to contribute significantly to the field of oncology with its bio-innovative drug solutions.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

OnKure Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by existing therapies. The company develops epigenetic therapies, including selective histone deacetylase inhibitors, and advances candidates such as OKI-179 and OKI-422 in preclinical and clinical development. Its approach aims to directly target malignant cells, combine with other targeted therapies, and prime the tumor microenvironment to enhance immunotherapies, with a pipeline of tumor-agnostic candidates designed for optimal efficacy and tolerability.

DTx Pharma, LLC is a biotechnology company headquartered in San Diego, California, specializing in the development and commercialization of fatty acid-conjugated peptide therapeutics. Founded in 2017, the company focuses on delivering RNA-based medicines to treat patients with rare and chronic diseases, including retinitis pigmentosa, Duchenne muscular dystrophy, and various central nervous system disorders. DTx Pharma's innovative delivery technology addresses challenges faced by previous-generation platforms, such as poor pharmacokinetics and limited cellular uptake, thereby enhancing the efficiency of nucleic acid drug delivery across diverse tissues and cell types. The company aims to establish RNA therapeutics as a leading option for personalized treatment in multiple therapeutic areas.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Visen Pharmaceuticals is an innovative biopharmaceutical company focused on developing and providing advanced treatments for endocrine diseases in China. With a patient-centric approach, Visen aims to deliver first-in-class or best-in-class products, covering both common and rare endocrine conditions in adults and children. The company leverages cutting-edge technologies and global resources, with established offices in Shanghai, Beijing, Hong Kong, and Taipei, along with a Greater China R&D and manufacturing site in Suzhou.

Biomea Fusion is a precision medicine company focused on accelerating cancer drug development by targeting specific gene alterations that drive tumor growth. Its lead program aims to disrupt the protein-to-protein interaction between menin and the MLL complex for treating various tumors.

Immuneering Corporation is a biotechnology company based in Cambridge, Massachusetts, with an additional office in New York, New York. Founded in 2008, it specializes in genetic, genomic, and proteomic data analysis for pharmaceutical clients, aiming to enhance the clinical and commercial success of medicines. The company utilizes advanced techniques such as gene expression analysis, proteomics, and next-generation sequencing to uncover biological insights that inform drug development. Immuneering's expertise in translational bioinformatics is applied throughout the drug development process, particularly for oncologic and neurologic diseases, and is integral to its proprietary computational platform, known as Disease Cancelling Technology. This platform supports drug discovery initiatives and provides computational biology services to both pharmaceutical and biotechnology companies, contributing to the creation of therapies for serious illnesses, including cancer and autoimmune diseases.

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. It leverages its proprietary transgene regulation platform, EXACT, to create gene therapies with the aim of addressing high-need conditions. The company’s pipeline includes NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. Founded in 2018, Neurogene is headquartered in New York and concentrates on advancing therapies that can improve outcomes for patients with limited treatment options.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

Flame Biosciences is a clinical-stage biotechnology company based in New York, founded in 2017. The company specializes in developing innovative therapies for cancer and other inflammatory conditions. Its portfolio includes FL-101 therapy, designed to treat lung cancers driven by inflammation, and FL-201, aimed at reducing chronic inflammation in patients. Flame Biosciences is dedicated to improving the lives of individuals suffering from debilitating and life-threatening diseases through its transformative therapeutic approaches.

Monte Rosa Therapeutics is a biotechnology company focused on cancer therapeutics that target protein degradation pathways. It specializes in developing molecular glue degraders, a class of small molecules that direct disease-relevant proteins to degradation by the cell's natural machinery. The company uses its QuEEN platform, incorporating artificial intelligence and proprietary experimental tools, to identify target proteins for degradation by molecular glue degraders. It maintains a diverse library of more than 50,000 molecules and advancing its pipeline, including MRT-2359, a candidate that targets the translation termination factor GSPT1 for potential use in MYC-driven tumors.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

I-Mab Biopharma (Shanghai) Co., Ltd. is a clinical-stage biopharmaceutical company based in Shanghai, China, with additional offices in Beijing and Rockville, Maryland. Founded in 2016, the company focuses on the discovery, development, and commercialization of innovative biologics aimed at addressing significant unmet medical needs, particularly in the fields of immuno-oncology and immuno-inflammation. I-Mab's diverse drug pipeline targets various therapeutic areas, including multiple myeloma, autoimmune diseases, pediatric growth hormone deficiency, and several cancer indications such as head and neck cancer. Key candidates in its portfolio include Uliledlimab, an antibody for solid tumors, along with Ragistomig and Givastomig, highlighting the company's commitment to developing transformative therapies for patients.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders marked by neuronal imbalance. Established in 2015 and headquartered in Cambridge, Massachusetts, the company leverages genetic insights to create innovative treatments for neurological and psychiatric conditions. Its leading product candidates include PRAX-114, an allosteric modulator targeting GABAA receptors, currently undergoing Phase IIa trials for major depressive disorder and perimenopausal depression, and PRAX-944, a selective inhibitor of T-type calcium channels in Phase IIa trials for essential tremor. Additionally, Praxis is advancing PRAX-562, a sodium current blocker in Phase I trials for severe pediatric epilepsy and adult cephalgia, along with PRAX-222, an antisense oligonucleotide aimed at treating patients with SCN2A epilepsy, and a program focused on KCNT1-related epilepsy. The company has established collaborations and licensing agreements with various organizations to enhance its research and development efforts.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Founded in 2019 and based in Cambridge, Massachusetts, MoMa Therapeutics discovers precision medicines by targeting molecular machines underlying human diseases. The company's platform enables drug development from previously intractable enzyme classes.

Tango Therapeutics is a biotechnology company focused on developing cancer therapies based on the genetic principle of synthetic lethality. It aims to counteract tumor suppressor gene loss, reverse immune evasion in cancer cells, and identify effective drug combinations.

Forma Therapeutics, headquartered in Watertown, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for rare hematologic diseases and various cancers. The company is advancing several key product candidates, including FT-4202, currently in Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. Additionally, Forma is developing FT-2102, a selective small molecule designed to inhibit mutated IDH1 enzymes, which is being evaluated in Phase 2 trials for relapsed/refractory acute myeloid leukemia and in exploratory trials for glioma. Other candidates include FT-4101 and FT-8225, selective inhibitors of fatty acid synthase. The firm integrates advanced drug discovery technologies with deep oncology expertise to address challenging targets, contributing to a robust pipeline aimed at transforming patient outcomes in oncology.

Avidity Biosciences is a biopharmaceutical company developing antibody oligonucleotide conjugates to enable tissue-selective delivery and precision RNA therapies for serious diseases. Its AOC platform combines monoclonal antibody tissue targeting with oligonucleotide therapies to access previously undruggable tissues and genetic drivers. The lead candidate, AOC 1001, targets myotonic dystrophy type 1, and its muscle programs address muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, and Pompe disease. The pipeline also includes immune and other cell-type programs, including Del-zota for DMD, Del-desiran for DM1, and Del-brax for FSHD. Avidity is based in La Jolla, California.

Neurogene is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. It leverages its proprietary transgene regulation platform, EXACT, to create gene therapies with the aim of addressing high-need conditions. The company’s pipeline includes NGN-401 for Rett syndrome and NGN-101 for CLN5 Batten disease. Founded in 2018, Neurogene is headquartered in New York and concentrates on advancing therapies that can improve outcomes for patients with limited treatment options.

Akero Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, with a primary emphasis on nonalcoholic steatohepatitis (NASH). Its lead program is a long-acting fibroblast growth factor 21 (FGF21) analog designed to restore metabolic balance and address liver fat, inflammation, and fibrosis. The company was founded in 2017 and is headquartered in South San Francisco, California.

Atreca is a biopharmaceutical company that discovers and develops antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from its proprietary discovery platform.

Avrobio is a clinical-stage biotechnology company focused on developing ex vivo lentiviral-based gene therapies to treat rare diseases with a single dose. Its pipeline includes AVR-RD-01 for Fabry disease, AVR-RD-02 for type 1 Gaucher disease, and AVR-RD-03 for Pompe disease.

Replimune Group is a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer treatment using its proprietary Immulytic platform. This platform aims to maximize systemic immune activation against tumor antigens through viral-mediated immunogenic tumor cell killing and delivery of optimal immune-activating proteins.

Atreca is a biopharmaceutical company that discovers and develops antibody-based immunotherapeutics for various solid tumor types. Its lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from its proprietary discovery platform.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Zai Lab is a biopharmaceutical company dedicated to discovering and developing transformative medicines for cancer, autoimmune, and infectious diseases. Founded in Shanghai in 2014, the company focuses on bringing innovative therapies to patients worldwide. Zai Lab's pipeline includes proprietary drug candidates such as Niraparib, Optune, Ripretinib, and Margetuximab, among others. The company collaborates with global biopharma leaders to expand its pipeline and foster innovation in China.

Mersana Therapeutics is a clinical-stage biopharmaceutical company that develops antibody-drug conjugates (ADCs) for cancer patients with unmet medical needs. It leverages proprietary ADC platforms, including Dolaflexin, Dolasynthen, and Immunosynthen, to create a diverse pipeline of product candidates designed to improve therapeutic benefit and address oncology indications underserved by traditional ADCs. The lead candidate XMT-1536 targets NaPi2b and is in Phase I trials for ovarian cancer, non-small cell lung cancer, and other indications. The company also advances additional programs such as Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175, reflecting its focus on next-generation ADCs. Mersana is headquartered in Cambridge, Massachusetts, and was founded in 2005.

ImmuneXcite, Inc. is a biopharmaceutical company based in Lexington, Massachusetts, specializing in the development of monoclonal antibodies for cancer treatment. Founded in 2007, the company utilizes its proprietary mAbXcite platform technology to enhance the efficacy of therapeutic monoclonal antibodies. This innovative approach involves chemically linking a unique carbohydrate, initially discovered at the Whitehead Institute at MIT, to monoclonal antibodies, thereby activating neutrophils to target and destroy cancer cells. ImmuneXcite's focus is on leveraging both innate and adaptive immune responses to create next-generation immune-activating biotherapeutics that address a wide range of tumor types, aiming to limit tumor growth and metastasis effectively. The company's research and development efforts have garnered support from various esteemed institutions and organizations, including the Massachusetts Technology Transfer Center and the National Cancer Institute.

Quanterix is a life sciences company that develops an ultra-sensitive digital immunoassay platform to advance precision health for research and diagnostics. Its Simoa platform employs bead-based and planar array technologies to detect protein biomarkers at very low concentrations in blood, serum, and other fluids that are undetectable by conventional assays. This enables early disease detection, improved prognosis, and more informed treatment decisions in clinical settings and research. The company provides instruments, assay kits, LDTs and assay services, as well as specialized modules and systems such as HD-X automated immunoassay analyzer, aiming to support biomarker analysis across healthcare and life science applications.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Founded in 2013, Twist Bioscience specializes in manufacturing and selling synthetic DNA-based products. Its innovative silicon-based DNA Synthesis Platform enables rapid, precise, high-throughput synthesis of DNA, serving customers in healthcare, agriculture, industrial chemicals, and data storage sectors.

C4 Therapeutics is a biopharmaceutical company developing targeted protein degradation therapies using its proprietary Degronimid platform. This platform enables the selective destruction of disease-causing proteins, expanding the scope of treatable conditions and potentially reducing drug resistance. The company focuses on oncology indications and has strategic collaborations with industry leaders.

Gelesis is a biotechnology company developing therapies to treat obesity and other gastrointestinal-related chronic diseases. It specializes in mechanobiology technology, with its lead product PLENITY being an orally-administered, non-stimulant aid for weight management.

Proteostasis Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies that regulate the body's protein homeostasis network to treat cystic fibrosis and other genetic or degenerative diseases. It develops Proteostasis Regulators intended to restore proteostasis balance and address conditions such as cystic fibrosis, emphysema, diabetes, and neurodegenerative disorders. In CF, its lead candidates include PTI-801, a CFTR corrector; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. The company collaborates with the Cystic Fibrosis Foundation to research, develop, and commercialize CF-related products, and has licensing relationships with Genentech. It was founded in 2006, formerly known as Proteoguard, and was renamed Proteostasis Therapeutics in 2007, based in Boston. It was acquired by Yumanity Therapeutics in 2020 in a reverse merger.

Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, designing, optimizing, and producing stereopure oligonucleotides through its PRISM platform. The company aims to address genetically defined diseases by reducing harmful protein expression or correcting dysfunctional proteins, employing modalities such as RNA editing, antisense silencing, and RNA interference. Its programs span neurological and neuromuscular conditions, reflecting an emphasis on central nervous system targets. Wave collaborates with Pfizer and Takeda on research, development, and commercialization of stereopure oligonucleotide therapeutics and antisense therapies. Founded in 2012 and based in Singapore, the company seeks to unlock the broader potential of RNA medicines to improve patient outcomes.

Ovid Therapeutics is a biopharmaceutical company focused on developing impactful medicines for patients with neurological disorders. Established in 2014, the company's pipeline includes OV101 (in Phase III for Angelman syndrome), OV935 (in Phase II for CDKL5 deficiency disorder and Dravet syndrome), and other programs targeting rare epilepsies and seizure-related disorders.

AnaptysBio is a clinical-stage biotechnology company focused on developing therapeutic antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company's pipeline includes immune cell modulating antibodies such as rosnilimab, a PD-1 agonist in Phase 2b trials for rheumatoid arthritis and ulcerative colitis, and ANB032, a BTLA agonist in Phase 2b trial for atopic dermatitis.

ContraFect Corporation is a clinical-stage biotechnology company based in Yonkers, New York, dedicated to developing innovative therapies for life-threatening and drug-resistant infectious diseases. Founded in 2008, the company focuses on creating therapeutic protein and antibody products, primarily using its proprietary lysin and monoclonal antibody platforms. Its lead candidate, CF-301, is an investigational lysin currently in Phase III trials for treating staphylococcus aureus bacteremia, including infections caused by methicillin-resistant strains. Additionally, ContraFect is advancing CF-296, which targets invasive staph aureus infections related to biofilms and osteomyelitis, and CF-370, aimed at gram-negative infections such as those caused by pseudomonas aeruginosa. The company also collaborates with The Rockefeller University to discover new lysin candidates targeting gram-negative pathogens and has initiated an expanded access program to provide exebacase for persistent bacteremia in COVID-19 patients.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Advaxis, Inc. is a clinical-stage biotechnology company based in Princeton, New Jersey, specializing in the development of immunotherapies for cancer and infectious diseases. The company utilizes a unique platform technology involving live, attenuated bacteria engineered to deliver antigen/adjuvant fusion proteins, effectively redirecting immune responses to target cancer cells. Advaxis is advancing several product candidates, including axalimogene filolisbac for HPV-related cancers, currently undergoing Phase II clinical trials for head and neck cancer. Additionally, it is developing ADXS-PSA for prostate cancer and ADXS-NEO, which personalizes treatment by using whole-exome sequencing to identify tumor neoantigens. Other projects include ADXS-HOT, aimed at generating robust anti-cancer immunity, and ADXS-HER2, designed to target HER2-expressing solid tumors. The company has established collaborations and licensing agreements with various organizations, enhancing its research and development efforts.

Fore Biotherapeutics is a precision oncology company focused on developing targeted cancer therapies guided by functional genomics. It aims to create a pipeline of treatments for patients with currently unaddressed mutations across established oncology targets.